UBS Group AG - FOAMIX PHARMACEUTICALS LTD ownership

FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 57 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q2 2017. The put-call ratio across all filers is 21.31 and the average weighting 0.2%.

Quarter-by-quarter ownership
UBS Group AG ownership history of FOAMIX PHARMACEUTICALS LTD
ValueSharesWeighting
Q4 2019$8,000
-76.5%
2,427
-78.4%
0.00%
Q3 2019$34,000
+1600.0%
11,253
+1025.3%
0.00%
Q2 2019$2,000
-77.8%
1,000
-58.6%
0.00%
Q1 2019$9,000
-99.9%
2,413
-99.9%
0.00%
-100.0%
Q4 2018$6,222,000
+15075.6%
1,732,997
+24229.6%
0.00%
Q3 2018$41,000
+64.0%
7,123
+44.3%
0.00%
Q2 2018$25,000
+400.0%
4,936
+393.6%
0.00%
Q1 2018$5,000
-37.5%
1,000
-22.9%
0.00%
Q4 2017$8,000
-76.5%
1,297
-78.3%
0.00%
Q3 2017$34,000
+580.0%
5,967
+496.7%
0.00%
Q2 2017$5,0000.0%1,0000.0%0.00%
Q1 2017$5,000
-72.2%
1,000
-38.1%
0.00%
Q4 2016$18,000
-28.0%
1,615
-38.6%
0.00%
Q3 2016$25,000
+177.8%
2,629
+78.0%
0.00%
Q2 2016$9,000
-59.1%
1,477
-55.4%
0.00%
Q1 2016$22,000
+46.7%
3,311
+86.5%
0.00%
Q4 2015$15,000
+36.4%
1,775
+23.1%
0.00%
Q3 2015$11,000
-88.9%
1,442
-85.1%
0.00%
Q2 2015$99,000
+280.8%
9,652
+237.8%
0.00%
Q1 2015$26,0002,8570.00%
Other shareholders
FOAMIX PHARMACEUTICALS LTD shareholders Q2 2017
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 4,781,708$28,738,0004.90%
DSC Advisors, L.P. 1,187,604$7,138,0004.14%
Opaleye Management Inc. 960,000$5,769,0001.85%
DAFNA Capital Management LLC 352,741$2,120,0001.14%
Vivo Capital, LLC 855,000$5,139,0001.10%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 382,838$2,301,0000.81%
SENZAR ASSET MANAGEMENT, LLC 377,397$2,268,0000.58%
Sio Capital Management, LLC 131,200$789,0000.44%
Perceptive Advisors 1,117,324$6,715,0000.22%
Tekla Capital Management LLC 930,398$5,592,0000.22%
View complete list of FOAMIX PHARMACEUTICALS LTD shareholders